Inhibiting SREBP activity through genetic or pharmacological suppression of HSP90β has been demonstrated to greatly improve fatty liver disease, type 2 diabetes, and atherosclerosis caused by obesity. This evidence concerns the gene HSP90AB1 and atherosclerosis.